🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s SUPN Holdings & Trades

First Buy
Q3 2014
Duration Held
40 Quarters
Largest Add
Q2 2020
+690,600 Shares
Current Position
1.71 M Shares
$88.14 M Value

Renaissance Technologies (RenTech)'s SUPN Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.71 M shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $88.14 M, representing 0.14% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 40 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in SUPN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2020, adding 690,600 shares. Largest reduction occurred in Q3 2018, reducing 416,790 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Supernus Pharmaceuticals (SUPN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Supernus Pharmaceuticals (SUPN) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 -27,300 Reduce 1.58% 1.71 M $51.69
Q4 2025 -8,100 Reduce 0.47% 1.73 M $49.70
Q3 2025 +85,300 Add 5.15% 1.74 M $47.79
Q2 2025 +69,600 Add 4.39% 1.66 M $31.52
Q1 2025 -13,000 Reduce 0.81% 1.59 M $32.75
Q4 2024 -129,900 Reduce 7.51% 1.6 M $36.16
Q3 2024 +43,500 Add 2.58% 1.73 M $31.18
Q2 2024 +351,900 Add 26.39% 1.69 M $26.75
Q1 2024 -45,200 Reduce 3.28% 1.33 M $34.11
Q4 2023 -60,000 Reduce 4.17% 1.38 M $28.94
Q3 2023 -57,900 Reduce 3.87% 1.44 M $27.57
Q2 2023 +102,800 Add 7.38% 1.5 M $0.03
Q1 2023 +133,000 Add 10.55% 1.39 M $0.04
Q4 2022 -19,700 Reduce 1.54% 1.26 M $0.04
Q3 2022 -116,800 Reduce 8.36% 1.28 M $33.85
Q2 2022 +153,500 Add 12.34% 1.4 M $28.92
Q1 2022 +4,400 Add 0.36% 1.24 M $32.32
Q4 2021 -149,500 Reduce 10.77% 1.24 M $29.16
Q3 2021 -127,600 Reduce 8.42% 1.39 M $26.67
Q2 2021 -244,000 Reduce 13.86% 1.52 M $30.79
Q1 2021 -89,300 Reduce 4.83% 1.76 M $26.18
Q4 2020 -18,978 Reduce 1.02% 1.85 M $25.16
Q3 2020 +275,700 Add 17.31% 1.87 M $20.84
Q2 2020 +690,600 Add 76.55% 1.59 M $23.75
Q1 2020 -18,900 Reduce 2.05% 902,200 $17.99
Q4 2019 +358,900 Add 63.84% 921,100 $23.72
Q3 2019 -42,000 Reduce 6.95% 562,200 $27.48
Q2 2019 +141,900 Add 30.69% 604,200 $33.09
Q1 2019 +118,800 Add 34.59% 462,300 $35.04
Q4 2018 -124,400 Reduce 26.59% 343,500 $33.22
Q3 2018 -416,790 Reduce 47.11% 467,900 $50.35
Q2 2018 +580,990 Add 191.30% 884,690 $59.85
Q1 2018 +277,600 Add 1063.60% 303,700 $45.80
Q4 2017 +26,100 New Buy 26,100 $39.85
Q4 2015 -125,100 Sold Out 0 $0.00
Q3 2015 +10,100 Add 8.78% 125,100 $14.03
Q2 2015 +115,000 New Buy 115,000 $16.98
Q1 2015 -157,049 Sold Out 0 $0.00
Q4 2014 +120,349 Add 327.93% 157,049 $8.30
Q3 2014 +36,700 New Buy 36,700 $8.69

Renaissance Technologies (RenTech)'s Supernus Pharmaceuticals Investment FAQs

Renaissance Technologies (RenTech) first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q3 2014, acquiring 36,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Supernus Pharmaceuticals, Inc. (SUPN) for 40 quarters since Q3 2014.

Renaissance Technologies (RenTech)'s largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q2 2020, adding 1,592,800 shares worth $37.83 M.

According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,705,222 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $88.14 M.

As of the Q1 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.14% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 1,868,500 shares, as reported at the end of Q3 2020.